Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Innate Pharma SA
< Previous
1
2
3
4
Next >
Innate Pharma to Participate in Upcoming Investor Conferences
November 02, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma 2023 Financial Calendar
October 20, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides
September 23, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Reports First Half 2022 Financial Results and Business Update
September 15, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update
September 08, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022
September 05, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Participate in Upcoming Investor Conferences
August 23, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2022
August 08, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
August 01, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Participate in Upcoming Investor Conference
July 28, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development
July 21, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Participate in Upcoming Investor Conference
June 23, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Participate in Upcoming Investor Conferences
May 11, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Reports First Quarter 2022 Financial Results and Business Update
May 10, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Number of Shares and Voting Rights of Innate Pharma as of May 1, 2022
May 10, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq
May 03, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update
May 03, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
April 29, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022
April 08, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Files Its 2021 Universal Registration Document (Document d’enregistrement universel) and 2021 Annual Report on Form 20-F
April 05, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Reports Full Year 2021 Financial Results and Business Update
March 24, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results
March 17, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Number of Shares and Voting Rights of Innate Pharma as of February 1, 2022
February 15, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Participate in Upcoming Investor Conferences
February 04, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans
January 05, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Participate in Upcoming Investor Conferences
January 04, 2022
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers
December 16, 2021
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress
December 02, 2021
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma to Participate in the Evercore ISI 4th Annual HealthConX Virtual Conference
November 24, 2021
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
Innate Pharma Announces Conference Call and Webcast for Q3 2021 Business Update
November 09, 2021
From
Innate Pharma SA
Via
Business Wire
Tickers
IPHA
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.